title: S-1 combined with cisplatin chemotherapy for advanced gastric cancer.
abstract: OBJECTIVE
  To observe the short-term efficacy and safety of S-1 combined with cisplatin (DDP) chemotherapy for advanced gastric cancer (AGC).
  
  
  METHODS
  Sixty-six patients were diagnosed with AGC and were admitted to our department from February 2012 to January 2015 and retrospectively analyzed. Of these patients, 31 (experimental group) underwent S-1 combined with DDP chemotherapy and 35 received oxaliplatin combined with tegafur and calcium folinate chemotherapy regimen (control group). The chemotherapy regimen for the experimental group included S-1, 60 mg bid on d1-d14 and 60 mg/m 2 DDP by intravenous dripping on d1-d3, with 4 weeks in a cycle. The chemotherapy regimen for the control group consisted of 130 mg/m 2 oxaliplatin by intravenous dripping, d1; 600 mg/m 2 tegafur by intravenous dripping on d1-d5; and 120 mg/m 2 calcium folinate by intravenous dripping on d1-d5, with 3 weeks in a cycle. The efficacies and adverse effects of the two regimens were assessed after three cycles.
  
  
  RESULTS
  After three cycles, the objective response rates of the experimental and control groups were 41.94% and 42.86%, without significantly difference (P > 0.05), respectively. However, the incidence rate of adverse drug reactions in Grades 3-4 in the experimental group was significantly lower than that of control group (P < 0.05).
  
  
  CONCLUSIONS
  The short-term efficacy of primary S-1 with DDP chemotherapy for AGC is relatively satisfactory with less adverse effects.
authors.affiliation: Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000, PR China.
authors.forename: Chen
authors.initials: C
authors.lastname: Weidong
authors.affiliation: Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000, PR China.
authors.forename: Xia
authors.initials: X
authors.lastname: Lijun
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016017:Odds Ratio; D010094:Oxonic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin